Genmab — September 2020
-
Ang. artikel bibob linkede til (Novel triplet combos...) - Joshua Richter, MD fra Mount Sinai siger: "Daratumumab, pomalidomide, and dexamethasone is already a utilized regimen, but [the supporting data] was from the phase 1/2 data EQUULEUS trial. Here, with isatuximab, we see the direct head-to-head comparison and the superiority of isatuximab, pomalidomide, and dexamethasone." Har han ret - er isa bedre end dara i denne kombi?
-
Sukkeralf. Her er Andrew Carlsens svar: “Det kan jeg ikke bekræfte. Vi ved at Janssen har startet yderligere en mere DuoBody program så vi nu har 7 i klinisk forsøg men har ikke fået oplyst hvad det hedder.”
-
08:23 isa/Pom/dex head to head studie blev ikke kørt mod dara/pom/dex. Så derfor kan man ikke konkludere at isa er bedre end dara
-
Bryan Garnier: Sell rating confirmed and TP decreased to DKK2000
-
-
Handelsbanken: http://prntscr.com/unlhzj
-
GENMAB A/S GMAB.CO: GUGGENHEIM RAISES PRICE TARGET TO DKK 2684 FROM DKK 2568 - Reuters News
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind